or Try an Advanced Search...

    Technical Analysis for AVTE - Aerovate Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 21.98 4.59% 0.97
    AVTE closed up 8.97 percent on Wednesday, May 15, 2024, on 1.94 times normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical AVTE trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 4.59%
    Crossed Above 20 DMA Bullish 4.59%
    MACD Bullish Signal Line Cross Bullish 4.59%
    Stochastic Buy Signal Bullish 4.59%
    Pocket Pivot Bullish Swing Setup 4.59%
    Bollinger Band Squeeze Range Contraction 4.59%
    Multiple of Ten Bullish Other 4.59%
    Gapped Up Strength 4.59%
    Slingshot Bearish Bearish Swing Setup 13.98%
    Pocket Pivot Bullish Swing Setup 13.98%
    Older End-of-Day Signals for AVTE ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 1 hour ago
    Up 3% about 2 hours ago
    60 Minute Opening Range Breakout about 3 hours ago
    Up 2% about 3 hours ago
    20 DMA Support about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    AVTE Chart by TradingView
    Basic chart:

    Profile

    Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Chemical Compounds Hypertension Orphan Drug Pulmonary Arterial Hypertension Pulmonary Hypertension Imatinib Piperazines

    Is AVTE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Aerovate Therapeutics reports Q1 GAAP EPS of -$0.83
    May 13 Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
    Apr 4 Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares
    Mar 27 Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
    Mar 27 Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023
    Mar 25 Aerovate Therapeutics reports FY results
    Mar 25 Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
    Mar 21 Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)
    Mar 21 Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...
    Mar 6 Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
    See more AVTE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 32.415
    52 Week Low 9.41
    Average Volume 172,364
    200-Day Moving Average 18.23
    50-Day Moving Average 24.19
    20-Day Moving Average 20.95
    10-Day Moving Average 20.40
    Average True Range 1.77
    RSI (14) 46.24
    ADX 14.66
    +DI 19.14
    -DI 19.54
    Chandelier Exit (Long, 3 ATRs) 20.27
    Chandelier Exit (Short, 3 ATRs) 23.68
    Upper Bollinger Bands 22.89
    Lower Bollinger Band 19.00
    Percent B (%b) 0.52
    BandWidth 18.60
    MACD Line -1.14
    MACD Signal Line -1.19
    MACD Histogram 0.0544
    Fundamentals Value
    Market Cap 581.32 Million
    Num Shares 27.7 Million
    EPS -2.74
    Price-to-Earnings (P/E) Ratio -7.67
    Price-to-Sales 0.00
    Price-to-Book 4.52
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 23.05
    Resistance 3 (R3) 22.85 21.97 22.71
    Resistance 2 (R2) 21.97 21.45 22.07 22.60
    Resistance 1 (R1) 21.49 21.13 21.73 21.69 22.48
    Pivot Point 20.61 20.61 20.73 20.71 20.61
    Support 1 (S1) 20.13 20.09 20.37 20.33 19.54
    Support 2 (S2) 19.25 19.77 19.35 19.42
    Support 3 (S3) 18.77 19.25 19.31
    Support 4 (S4) 18.97